Taking Sialic Acid to Regulate the Gut MicrobiotaHealthy
Investigational drug(s) / intervention(s)
Oral Sialic acid
Oral Sialic acid: This study employs a before-after self-control trial design, recruiting 42 volunteers to take oral sialic acid and collecting fecal samples before and after the intervention.
Study summary
This is a single-center prospective cohort study conducted by the Department of General Surgery at the Second Affiliated Hospital of Army Medical University (Xinqiao Hospital). The purpose of this study is to explore and clarify the effects of sialic acid intervention on gut microbiota structure, with a focus on the proliferation of pathogens (e.g., Escherichia coli, Klebsiella pneumoniae), and to develop novel prevention and treatment strategies for improving intestinal homeostasis.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Aged between 18 and 75 years
* No history of major diseases, no previous surgical history, and no history of cardiometabolic diseases (such as hypertension, diabetes mellitus, obesity, etc.)
* No use of drugs that may affect gut microbiota or metabolic function (e.g., antibiotics, probiotics, immunosuppressants, etc.);
* Voluntarily participate in the study and sign the informed consent form.
Exclusion Criteria:
* Comorbidities: Complicated with other severe diseases (e.g., immunodeficiency, chronic liver disease, renal insufficiency, malignant tumors, etc.).
* Recent infections: Registration records indicate a history of severe infections in the recent period (within 3 months) or currently receiving anti-infective treatment.
* Special populations: Pregnant women, lactating women, or women planning to become pregnant.
* Poor compliance: Volunteers who are unable to cooperate with the study protocol or follow-up
Primary outcome measure(s)
Alterations in Gut Microbiota Structure — From enrollment to the end of treatment at 2 weeks Gut microbiota data analysis: Perform sequence analysis and OTU clustering using QIIME2 or Mothur; compare microbial diversity (α-diversity and β-diversity) between the experimental group and control group, as well as changes in the abundance of specific microbiota (e.g., Escherichia coli, Klebsiella pneumoniae); use LEfSe analysis to screen for microbiota with significant changes after sialic acid intervention, and predict changes in microbial functions via PICRUSt
Trial sites (1)
Facility
City
Region
Status
Second Affiliated Hospital of Army Medical University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.